Under construction – not a live service
Sign in
Taking people in AustraliaPhase 2

Tirzepatide Effects on Metabolism in Type 1 Diabetes

Tests tirzepatide against placebo in adults with type 1 diabetes.

Plain-language title generated from the registry record
Registry title: Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes

Key facts

Where
Sydney, AustraliaSee the site
Phase
Phase 2

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18-70 with type 1 diabetes who use an automated insulin delivery system and have a BMI of 25 or more. It tests tirzepatide against placebo for 6 weeks.

Age
18 to 70 years
Sex
All sexes can join.
Disease stage
Type 1 diabetes for at least 2 years, with HbA1c of 9.0% (75 mmol/mol) or lower.
Earlier treatment
Must use an automated insulin delivery system. Cannot have taken tirzepatide or a GLP-1 receptor agonist in the last 3 months, or metformin, an SGLT2 inhibitor, systemic steroids or antipsychotics in the last 6 weeks.
Biomarker or test result
BMI of 25 kg/m2 or more. HbA1c of 9.0% (75 mmol/mol) or lower.

Main reasons for not taking part

  • Hypoglycemic unawareness, or severe hypoglycemia in the last 6 months
  • History of seizure disorder or weight loss surgery
  • Kidney problems (eGFR below 60 mL/min/1.73 m2) or liver disease
  • Pregnant, breastfeeding, or planning pregnancy within 6 months
  • Heart event or stroke in the last 6 months, active malignancy, or active or untreated proliferative diabetic retinopathy

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Source: NCT06820281, who can take part

Where in Australia

  • Victor Chang Cardiac Research InstituteSydney, AustraliaContact: Jennifer R Snaith, MD/PhDTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Victor Chang Cardiac Research Institute
Trial code
NCT06820281
Record updated
16 September 2026
Original description
This study will examine the effects of Tirzepatide (TZP), a glucagon-like peptide 1 (GLP1) - gastric inhibitory peptide (GIP) co-agonist, on metabolism in type 1 diabetes (T1D). Research participants with T1D will undergo measures of insulin sensitivity, and hormone levels post-meal, post-hypoglycemia and during the overnight period. These measures will be performed prior to, and after 6 weeks of treatment with TZP or placebo.Read full original descriptionShow less

Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes: a Phase 2 Double Blinded Placebo Controlled Clinical Trial (TIRTLE2)

This study will examine the effects of Tirzepatide (TZP), a glucagon-like peptide 1 (GLP1) - gastric inhibitory peptide (GIP) co-agonist, on metabolism in type 1 diabetes (T1D). Research participants with T1D will undergo measures of insulin sensitivity, and hormone levels post-meal, post-hypoglycemia and during the overnight period. These measures will be performed prior to, and after 6 weeks of treatment with TZP or placebo.

Inclusion: age 18-70 years; BMI ≥ 25 kg/m2; HbA1c ≤ 9.0%; insulin delivery using an automated insulin delivery system; at least 2 years since diagnosis of type 1 diabetes.

Exclusion: History of seizure disorder; History of weight loss surgery; Liver disease (known cirrhosis, LFTs > 3x upper limit of normal); Active malignancy; Coronary event or stroke in last 6 months; TZP or GLP-1 receptor agonist in last 3 months; metformin or sodium glucose co-transporter 2 (SGLT2) inhibitor in the last 6 weeks; systemic steroids, antipsychotics, in the last 6 weeks; eGFR <60 mL/min/1.73 m2; Hemoglobin level < 13.5 g/dL in men, < 12.0 g/dL in women; Hypoglycemic unawareness or severe hypoglycemia last 6 months; Pregnant, breastfeeding, planning pregnancy within 6 months, or not using adequate contraception; Active or untreated proliferative diabetic retinopathy.

ClinicalTrials.gov NCT06820281